Loren Data's SAM Daily™

FBO DAILY - FEDBIZOPPS ISSUE OF OCTOBER 01, 2015 FBO #5060
DOCUMENT

Q -- 626-16-1-097-0009 SPECIAL TESTING - Attachment

Notice Date

9/29/2015
 

Notice Type

Attachment
 

NAICS

621511 — Medical Laboratories
 

Contracting Office

Department of Veterans Affairs;Network Contracting Office 9;1639 Medical Center Parkway;Suite 400;Murfreesboro TN 37129
 

ZIP Code

37129
 

Solicitation Number

VA24916Q10844
 

Response Due

10/5/2015
 

Archive Date

1/12/2016
 

Point of Contact

David Spicer
 

Small Business Set-Aside

Total Small Business
 

Description

Statement of Work Specialized Cancer Testing COR: Shannon Skillern, 615-873-7589 Shannon.skillern@va.gov Requirements: 1.Requirements TVHS needs a vendor to perform the following special cancer tests: Oncotype DX Breast Cancer Assay, the Oncotype DX Colon Cancer Assay and the Oncotype DX Prostate Cancer Assay, which are trademarked tests by Genomic Health. The required testing will analyze the activity of a group of genes that can affect how a cancer is likely to behave and respond to treatment. Testing results need to show how complex genes are expressed in cells (what their level of activity is), and the role they play in specific cancers including breast, colon, and prostate. TVHS will only accept tests of equivalent or higher performance to the Oncotype DX test. Equivalent tests must show clinical evidence and at least three years on the market in labs (outside of research purposes). The VA TVHS requires testing that has been reliable for years and will not risk experimenting with newer specialized cancer tests unless evidence guarantees greater benefits to Veterans. The requested tests have been proven to predict the likelihood of cancer recurrence, the likelihood of patient survival and the likelihood of chemotherapy benefit. These unique diagnostic tests can help patients and their doctors make informed, individualized treatment decisions. Results will also help clinicians determine if the patient needs to undergo chemotherapy treatment or not, saving the VA thousands of dollars in treatment costs. 2.Scope. Indefinite delivery, indefinite quantity (IDIQ) of cancer testing, with the required tests listed in the chart under "Specific Tasks." Estimated yearly cost for FY16 is $12,000 based on FY14 and FY15 usage. This amount may be changed based on clinical needs of patients. 3.Specific Tasks (Evaluation Factors). The Reference Laboratory shall provide in accordance with all applicable federal, state, and local regulations, laws, and ordinances, and in accordance with the specifications outlined for accreditation certification if applicable, patient testing to aid in the treatment of cancer. Estimated quantities of tests will depend upon patient specifics. Vendor must offer all tests listed in the test menu below. TVHS will only accept tests of equivalent or higher performance to the Oncotype DX test. Equivalent tests must show clinical evidence and at least three years on the market in labs (outside of research purposes). TEST MENU: Following tests must be available from vendorRate not to exceed Oncotype DX Breast Cancer Assay $3,416 Oncotype DX Colon Cancer Assay $3,104 Oncotype DX Prostate Cancer Assay $3,450 4.Performance Monitoring Performance monitoring will be done by a third party, the organization that the reference lab has accreditation through. The reference lab will maintain on file their current accreditation and make it available for review upon request. 5.Government-Furnished Equipment (GFE)/Government-Furnished Information (GFI). None 6.Other Pertinent Information or Special Considerations. a.Identification of Possible Follow-on Work. NA b.Identification of Potential Conflicts of Interest (COI). All parties involved with the review and establishment of this request should not have any conflicts of interest with the chosen vendor. c.Identification of Non-Disclosure Requirements. NA d.Packaging, Packing and Shipping Instructions. As indicated on requisition form, or on posted test preparation guidelines. e.Inspection and Acceptance Criteria. See performance monitoring 7.Risk Control NA 8.Place of Performance. Reference laboratory.
 

Web Link

FBO.gov Permalink
(https://www.fbo.gov/spg/VA/NaVAMC/VAMCCO80220/VA24916Q10844/listing.html)
 

Document(s)

Attachment
 

File Name: VA249-16-Q-10844 VA249-16-Q-10844.docx (https://www.vendorportal.ecms.va.gov/FBODocumentServer/DocumentServer.aspx?DocumentId=2344288&FileName=VA249-16-Q-10844-000.docx)

Link: https://www.vendorportal.ecms.va.gov/FBODocumentServer/DocumentServer.aspx?DocumentId=2344288&FileName=VA249-16-Q-10844-000.docx

 

Note: If links are broken, refer to Point of Contact above or contact the FBO Help Desk at 877-472-3779.
 

Record

SN03908218-W 20151001/150929235725-3f7787452ac4fc0dcf20f13d9fbbb68f (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |